Bendamustine plus rituximab vs. standard therapy for advanced CLL
Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel
Checkpoint inhibitors: parallel management of the disease and immune-related toxicities
Why has the biobank project been a success and what is the future for it?
Regis Peffault de Latour
Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib